Evaluation of a crosswalk between the European Quality of Life Five Dimension Five Level and the Menopause-Specific Quality of Life questionnaire

Abstract

Objectives: Postmenopausal (PM) women taking therapies using estrogens plus progestogens (EPTs) can experience side effects (breast pain, vaginal spotting/bleeding). Sensitivity of the European Quality of Life Five Dimension Five Level (EQ-5D-5L) in measuring quality of life of PM women experiencing side effects of EPTs is unknown. A crosswalk between the Menopause-Specific Quality of Life (MENQOL) questionnaire and the EQ-5D-5L was assessed.

Methods: The measures were administered to 352 PM women (side effects = 202; control = 75; untreated = 75) in a non-interventional study. MENQOL total scores, treated as continuous and categorical predictors, were mapped onto EQ-5D-5L utilities using regression. Ordinary least-squares regression using averaged scores over time, goodness of fit, and estimated coefficients was also assessed.

Results: Mean age was 53.7 years. The first model (MENQOL as a continuous variable) showed a moderate correlation (−0.589) and statistically significant relationship with the EQ-5D-5L (p < 0.001), with an equation of EQ-5D-5L = 0.992 − 0.042 × MENQOL. The EQ-5D-5L mean scores were comparable (side effects = 0.854; control = 0.927; untreated = 0.836) to MENQOL mean scores estimated in the first model (side effects = 0.865 [standard deviation 0.07]; control = 0.909; untreated = 0.833). Linearity assumptions were supported with MENQOL scores as a categorical predictor. Goodness of fit was moderate (R² = 0.347; root mean squared error = 0.093).

Conclusion: The crosswalk supports conversion of MENQOL scores to EQ-5D-5L-derived health utilities for group-level analyses in PM women.

Keywords:

• Postmenopause
• health utilities
• crosswalk
• women’s health
• patient-reported outcomes

Conflict of interest

Sophi Tatlock, Nicola Williamson and Rob Arbuckle are employees of Adelphi Values who were paid consultants by Pfizer in connection with this study. Lucy Abraham, Andrew Bushmakin and Maggie Moffat are employees of Pfizer. Cheryl Coon was an employee of Adelphi Values at the time the study was conducted. All authors reviewed and approved of the final manuscript.

Additional information

Funding

This project was funded by Pfizer, Inc.

This project was funded by Pfizer, Inc.